GlobeImmune, Inc. GlobeImmune, Inc.

GlobeImmune, Inc.

GBIM

Rank in Stocks #35033
GlobeImmune, Inc., a biopharmaceutical firm based in Louisville, Colorado, and... GlobeImmune, Inc., a biopharmaceutical firm based in Louisville, Colorado, and founded in 1995 (originally Ceres Pharmaceuticals, Inc. until its rebranding in May 2001), specializes in creating therapeutic products for both cancer and infectious diseases. Central to its development efforts is its unique Tarmogen platform. The company's pipeline includes several key candidates: For infectious diseases: GS-4774 is currently in Phase 2 clinical trials, designed to treat individuals chronically infected with the hepatitis B virus who are also on oral antiviral suppressive therapy. Additionally, GlobeImmune has various other infectious disease programs in the preclinical stage, such as GI-19000 for tuberculosis, GI-2010 for human immunodeficiency virus (HIV), and GI-18000 for hepatitis D virus infections. For oncology: GlobeImmune is advancing GI-6301, which targets cancers characterized by the expression of the brachyury protein. GI-6207 is progressing through Phase 2 clinical trials for medullary thyroid cancer. Furthermore, GI-4000 is a significant asset, undergoing Phase 2b clinical trials for resected pancreatic cancer, and is also in separate Phase 2 trials for non-small cell lung cancer and colorectal cancer. To support its endeavors, GlobeImmune maintains strategic alliances with industry leaders such as Gilead Sciences, Inc. and Celgene Corporation.
Share Price
$0.0001
Last synced: 2026-11-16
Market Cap
$575.16
Change (1 day)
0.00%
Change (1 year)
0.00%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
Operating Margin for GlobeImmune, Inc. (GBIM)
Operating Margin as of November 2026 TTM: -42.85%
According to GlobeImmune, Inc.'s latest financial reports, its current operating margin (TTM) is -42.85%. At the end of 2015 the company had an operating margin of -42.85%.
Operating Margin history for GlobeImmune, Inc. from 2010 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -42.85% 0.00%
2015 -42.85% -56.06%
2014 -97.53% -385.68%
2013 34.14% -226.02%
2012 -27.09% -89.01%
2011 -246.55% -36.34%
2010 -387.31% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
33.87% -100.79%
US
-116.04% -97.29%
US
25.57% -100.60%
AU
31.23% -100.73%
BE
29.35% -100.68%
NL
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about GlobeImmune, Inc.'s operating margin

What is GlobeImmune, Inc.'s operating margin?

GlobeImmune, Inc.'s operating margin is -42.85%, as of Nov 2026.

What was GlobeImmune, Inc.'s operating margin in 2015?

In 2015, GlobeImmune, Inc.'s operating margin was -42.85%, compared with -97.53% in 2014.

How has GlobeImmune, Inc.'s operating margin changed since 2010?

From 2010 to 2015, GlobeImmune, Inc.'s operating margin was highest in 2013 (34.14%) and lowest in 2010 (-387.31%).

How does GlobeImmune, Inc.'s operating margin compare with similar companies?

GlobeImmune, Inc.'s operating margin (-42.85%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.